| Sep 10 |
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
|
| Sep 9 |
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
|
| Aug 22 |
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 6 |
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
|
| Aug 2 |
Vir Biotechnology, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 2 |
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 1 |
Vir announces major restructuring, licensing deal with Sanofi
|
| Aug 1 |
Vir Biotechnology GAAP EPS of -$1.02 misses by $0.06, revenue of $3.07M misses by $4.43M
|
| Aug 1 |
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
|
